Fig. 6

In vivo therapeutic efficacy of SVV-001 acting alone and in combination with fractionated radiation. a Treatment scheme and log-rank analysis of animal survival times. Radiation was administered at 2 Gy/day × 5 days after which SVV-001 (1 × 10¹¹vp/cell) was administered via tail vein injection. Changes of animal survival times were compared via log-ranks analysis. Median survival times in IC-K012GBM were 46 days in control group, 50 days in SVV-001 only group, 59 days in XRT only, and 69 days in the combination; whereas in IC-A46GBM, they were 42 days in control group, 53 days in SVV-001 only, 74 days in XRT only, and 88 days in the combination. b Summary of pairwise comparison of the treated groups using Holm–Sidak method. P < 0.05 is significant. c, d Images and summary of time-course IHC analysis of DNA damage (rH2AX) in PDOX tumors of IC-K012GBM following XRT and/or SVV-001 treatment. (Scale bar: 50 µM)